Targeted proteoform degradation for precision drug design, delivery, and therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• The ubiquitin-proteasome system (UPS) is crucial for protein homeostasis and disease.
• Proteolysis-targeting chimeras (PROTACs) advance targeted protein degradation (TPD) beyond traditional inhibitors.
• Current TPD focuses on proteins, overlooking proteoform diversity.

Purpose of the Study:

• Introduce targeted proteoform degradation (TPfD) as a novel approach.
• Highlight the limitations of current TPD in distinguishing protein variants.
• Propose TPfD for enhanced precision in drug development and disease treatment.

Main Methods:

• Review of protein-based TPD and PROTAC technology.
• Elaboration on the concept and technical foundations of TPfD rooted in proteoformics.
• Discussion of design methodologies including ligand optimization, linker engineering, and E3 ligase selection.

Main Results:

• TPfD offers a more refined strategy than general protein targeting.
• Proteoformics enables recognition of subtle, functionally distinct protein alterations.
• TPfD facilitates precise targeting of pathology-specific proteoforms.

Conclusions:

• TPfD represents a significant advancement over conventional TPD.
• This approach holds promise for personalized drug development and optimized therapeutic regimens.
• TPfD is poised to refine therapeutic strategies for complex diseases within precision medicine.